S tudies on BMD in women with diabetes have conflicting results. Some studies originating from registries in the 1990s showed lower BMD levels in women with both types of diabetes.
S tudies on BMD in women with diabetes have conflicting results. Some studies originating from registries in the 1990s showed lower BMD levels in women with both types of diabetes. 1, 2 Recent studies have confirmed the deleterius effect of type 1 diabetes on bone density, 3 whereas a normal or even inc c creased BMD was noted in women with type 2 diabetes mellitus. 4 During these analyses, biochemical paramec c ters of calcium and phosphorus metabolism, lipid levels and statin therapy, glycated products levels, lifestyle and body mass index (BMI) were all identified as possible factors in altering BMD in women with type 2 diabec c tes.
5c7 Several studies explained the results of increased BMD in women with type 2 diabetes by their higher BMI, 8 although some mechanisms resulting from the hyperglycemic state, together with insulin resistance were also noted to improve BMD. 9 We conducted this study to determine whether postmenopausal women with type 2 diabetes mellitus have higher BMD than noncdiabetic women of similar age, and to investigate the relationship between BMD and relevant clinical characteristics in these groups of women.
PATIENTS AND METHODS
We retrospectively investigated 130 postmenopausal white women with type 2 diabetes mellitus who unc c derwent dual xcray bone absorptiometry (DXA) at the outpatient clinic of the Internal Medicine Department of Slavonski Brod General Hospital during a onecyear voluntary screening process in our community. Another 166 noncdiabetic postmenopausal white women who underwent DXA in the same period were randomly selected as controls from the women who underwent DXA. All studied women had the DXA measurec c ment for the first time, and had no previous history of low bone mass, osteoporosis or osteoporosis therapy.
Exclusion criteria included previously diagnosed osteoc c porosis, osteoporotic fracture or osteoporosis therapy. BMD of the lumbar spine, femoral neck and radic c us using DXA was measured in each patient, and exc c pressed as g/cm 2 . All measurements were performed using Hologic QDR 1000 (Texas Instruments), by the same technician involved in the screening process.
The tctest and the ManncWhitney test were used to investigate the differences in clinical characteristics bec c tween the two groups. The differences in BMD of the lumbar spine, femoral neck and radius between diabetic and noncdiabetic women were assessed using the tctest. Multiple regression analysis was used to investigate the effect of age, menarche and menopause age, BMI, and laboratory results (serum calcium, phosphorus, alkaline phosphatase, urine calcium and phosphorus, total choc c lesterol and triglycerides) on lumbar spine, femoral neck and radius BMD in both groups of women. The signific c cance level was set to P<.05.
RESULTS
There were no differences between the two groups of women in clinical characteristics, except that women with type 2 diabetes had significantly higher triglycerc c ides (Table 1) . Women with type 2 diabetes mellitus had significantly higher mean lumbar spine BMD (P<.001) and mean femoral neck BMD (P<.05) than noncdiabetc c ic women. There were no significant differences between the two groups in the mean radius BMD (Table 2 ).
In the diabetes group, multiple regression analysis showed a positive correlation of the femoral neck BMD with BMI (P<.05), and lumbar spine and radius BMD with menarche age (P<.05), while there was a negative correlation of the lumbar spine, femoral neck, and rac c dius BMD with age (P<.001) and alkaline phosphatase levels (P<.05).
The multiple regression analysis among noncdiabetic women revealed a positive correlation of the femoral neck BMD with BMI (P<.001) and urine phosphoc c rus (P<.05), and a positive correlation of the lumbar spine BMD with menopause age and BMI (P<.05). Conversely, there was a negative correlation of the lumc c bar spine and femoral neck BMD with age (P<.001). In addition, femoral neck BMD correlated negatively with serum phosphorus (P<.05).
DISCUSSION
Women with type 2 diabetes had higher BMD at all three observed sites than noncdiabetic women with comparable clinical characteristics. The difference was significant for lumbar spine and femoral neck (P<.001 and P<.05, respectively), whereas the difference in rac c dius BMD was not significant. Several recent studies in white women reported analogous findings, 4c9 whereas a recent study in an Arabic female population showed osc c teoporosis to be more common among postmenopausal females with type 2 diabetes. 10 Age and fertility duration were independently correlated with BMD levels. There were no significant differences in BMI between the two groups of women, and the positive correlation between femoral neck BMD and BMI was observed in both groups. Higher BMD in women with diabetes had been attributed to higher BMI, 8 although our results support several findings of higher BMD independent of BMI in women with diabetes. 11 Although the women with type 2 diabetes had similar serum alkaline phosphatase levels to those of women in the control group, we found that their serum alkaline phosphatase levels showed a negac c tive correlation with BMD. 7 Type 2 diabetes seems to be protective in the process of bone density loss, as we demonstrated in our study. However, an increased fracture risk in women with diac c betes was reported in many studies, and was attributed mainly to neurological and visual complications that fac c cilitate fall accidents, or low bone quality. 12 Today, there are sufficient data that support the concept of preserved bone density in hyperinsulinemia, thus the increased fracture risk in women with type 2 diabetes could also be explained by altering processes in new bone formac c tion and bone microarchitectural integrity in the hyperc c glycemic state. 12 The limitation of our study was the cross sectional dec c sign, and the inability to compare fracture risk between the observed groups, since fractures represent the most important aspect of osteoporosis. Fracture risk analyses require a higher number of patients from standardized registries, which does not exist in our clinical settings. It would be also interesting to assess the relationship bec c tween the duration of diabetes, and levels of glycation products with both BMD and fracture risk. Some studc c ies showed that good glycemic control prevents bone loss in both types of diabetes, explaining normal BMD levels in type 2 diabetes with better glycemic control. 13, 14 Our study could not show differences in BMD levels among women in relation to glycemic control.
We conclude that osteoporosis in women with type 2 diabetes needs a more scrutinized approach because BMD levels in diabetic women may not be sufficient in identifying those at risk for fractures, knowing that subc c stantial evidence exists of their increased fracture risk. A better understanding of diabetes and osteoporosis may help preventing fractures in the growing population of postcmenopausal women with type 2 diabetes mellitus.
